MCID: HMP009
MIFTS: 45

Haemophilus Influenzae malady

Categories: Rare diseases, Infectious diseases

Aliases & Classifications for Haemophilus Influenzae

Summaries for Haemophilus Influenzae

MalaCards based summary : Haemophilus Influenzae, also known as h. influenzae, is related to fasciitis and aseptic meningitis. An important gene associated with Haemophilus Influenzae is OMP (Olfactory Marker Protein), and among its related pathways/superpathways are Toll-like Receptor Signaling Pathway and IL-17 Family Signaling Pathways. The drugs Amoxicillin and Estradiol have been mentioned in the context of this disorder. Affiliated tissues include colon, lung and tonsil, and related phenotypes are hematopoietic system and homeostasis/metabolism

Wikipedia : 71 Haemophilus influenzae (formerly called Pfeiffer\'s bacillus or Bacillus influenzae) is a Gram-negative,... more...

Related Diseases for Haemophilus Influenzae

Diseases related to Haemophilus Influenzae via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 182)
id Related Disease Score Top Affiliating Genes
1 fasciitis 30.1 CXCL8 TLR2 TNF
2 aseptic meningitis 29.6 TLR2 TNF
3 epiglottitis 11.4
4 haemophilus meningitis 11.3
5 c3 deficiency 11.0
6 influenza 11.0
7 bronchitis 10.7
8 tetanus 10.6
9 pertussis 10.5
10 diphtheria 10.5
11 meningitis 10.5
12 pneumonia 10.5
13 hepatitis 10.4
14 hepatitis b 10.4
15 otitis media 10.4
16 myeloid proliferations related to down syndrome 10.2 CXCL8 TLR2
17 conidiobolomycosis 10.2 CXCL8 TNF
18 thymic neuroendocrine carcinoma 10.2 CXCL8 TNF
19 myoclonic astatic epilepsy 10.2 CXCL8 TLR2
20 nephronophthisis 1, juvenile 10.2 CXCL8 TNF
21 plantar wart 10.2 CXCL8 TNF
22 esophagus lymphoma 10.2 CXCL8 TNF
23 coronary arterial fistulas 10.2 CXCL8 LTF
24 sutton disease 2 10.2 LTF TF
25 psychotic disorder 10.2 CXCL8 LTF
26 amyotrophic lateral sclerosis type 14 10.2 CXCL8 TNF
27 rosette-forming glioneuronal tumor of fourth ventricule 10.2 LTF TF
28 retinal vascular disease 10.2 CXCL8 LTF
29 scleroderma, familial progressive 10.2 CXCL8 LTF
30 poliomyelitis 10.2
31 spotted fever 10.2 TLR2 TNF
32 coumarin resistance 10.2 CXCL8 VTN
33 parkinson disease 11 10.2 CXCL8 TNF
34 aortic coarctation 10.1 TLR2 TNF
35 total internal ophthalmoplegia 10.1 CLEC7A CXCL8
36 cellulitis 10.1
37 rubella 10.1
38 mumps 10.1
39 measles 10.1
40 fungal gastritis 10.1 CXCL8 TNF VTN
41 alcoholic hepatitis 10.1 CXCL8 TF TNF
42 nystagmus, congenital motor, autosomal recessive 10.1 TLR2 TNF
43 nasopharyngitis 10.1
44 right ventricle hypoplasia 10.1 LTF TNF
45 ulcerative proctitis 10.1 CXCL8 TLR2 TNF
46 trichomalacia 10.1 CXCL8 TNF
47 inappropriate adh syndrome 10.1 CXCL8 TLR2 TNF
48 ovarian cystic teratoma 10.1 CXCL8 TLR2 TNF
49 atrophy of prostate 10.1 CXCL8 TLR2 TNF
50 unilateral hypoactive labyrinth 10.1 CXCL8 TLR2 TNF

Graphical network of the top 20 diseases related to Haemophilus Influenzae:



Diseases related to Haemophilus Influenzae

Symptoms & Phenotypes for Haemophilus Influenzae

MGI Mouse Phenotypes related to Haemophilus Influenzae:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.92 LTF PKD1 TF TLR2 TNF VTN
2 homeostasis/metabolism MP:0005376 9.91 CLEC7A CYLD LTF OMP PKD1 TF
3 digestive/alimentary MP:0005381 9.77 CLEC7A CYLD PKD1 TLR2 TNF
4 neoplasm MP:0002006 9.55 CYLD LTF PKD1 TLR2 TNF
5 normal MP:0002873 9.43 CYLD LTF OMP PKD1 TLR2 VTN
6 respiratory system MP:0005388 9.1 CLEC7A CYLD OMP PKD1 TLR2 TNF

Drugs & Therapeutics for Haemophilus Influenzae

Drugs for Haemophilus Influenzae (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 132)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 26787-78-0 33613 2171
2
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757 53477783
3
Iron Approved Phase 4,Phase 3,Phase 2 7439-89-6 23925
4
Acetaminophen Approved Phase 4,Phase 3 103-90-2 1983
5
Ibuprofen Approved Phase 4 15687-27-1 3672
6
Azithromycin Approved Phase 4 83905-01-5 55185 53477736 447043
7
Norgestimate Approved Phase 4 35189-28-7 6540478
8
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
9
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
10
Edetic Acid Approved, Vet_approved Phase 4,Phase 3,Phase 2 60-00-4, 62-33-9 6049
11 Clavulanic Acid Phase 4,Phase 3,Phase 2
12 Amoxicillin-Potassium Clavulanate Combination Phase 4,Phase 3,Phase 2
13 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
14 Heptavalent Pneumococcal Conjugate Vaccine Phase 4,Phase 3,Phase 2,Phase 1
15 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3
16 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
17 Anti-Bacterial Agents Phase 4,Phase 3,Phase 1,Phase 2
18 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1
19 beta-Lactamase Inhibitors Phase 4,Phase 3,Phase 2
20 Anti-Infective Agents Phase 4,Phase 3,Phase 1,Phase 2
21 Fluoroquinolones Phase 4,Phase 3
22 Antibodies Phase 4,Phase 3,Phase 2,Phase 1
23 Estradiol valerate Phase 4 979-32-8
24 Analgesics Phase 4,Phase 3,Phase 1
25 Chelating Agents Phase 4,Phase 3,Phase 2
26 Contraceptive Agents Phase 4
27 Contraceptives, Oral Phase 4
28 Contraceptives, Oral, Combined Phase 4
29 Cyclooxygenase Inhibitors Phase 4
30 Norgestimate, ethinyl estradiol drug combination Phase 4
31 Analgesics, Non-Narcotic Phase 4,Phase 3
32 Ophthalmic Solutions Phase 4
33 Diphtheria Antitoxin Phase 4,Phase 3
34 Pentetic Acid Phase 4,Phase 3,Phase 2
35 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1
36 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1
37 Estradiol 17 beta-cypionate Phase 4
38 Estradiol 3-benzoate Phase 4
39 Polyestradiol phosphate Phase 4
40 Immunoglobulin G Phase 4,Phase 3
41 Anticoagulants Phase 4,Phase 3,Phase 2
42 Protective Agents Phase 4,Phase 3,Phase 2
43 Antidotes Phase 4,Phase 3,Phase 2
44 Anti-Inflammatory Agents Phase 4
45 Iron Chelating Agents Phase 4,Phase 3,Phase 2
46 Anti-Inflammatory Agents, Non-Steroidal Phase 4
47 MF59 oil emulsion Phase 4
48 Antipyretics Phase 4,Phase 3
49 Antirheumatic Agents Phase 4
50 Antitoxins Phase 4,Phase 3

Interventional clinical trials:

(show top 50) (show all 283)
id Name Status NCT ID Phase
1 Middle Meatal Bacteriology During Acute Respiratory Infection in Children Unknown status NCT00545961 Phase 4
2 Safety, Long Term Immunogenicity and Lot Consistency Study of Liquid Pentavalent Combination Vaccine Unknown status NCT00877357 Phase 4
3 Safety of Haemophilus Influenza Type b Vaccine When Administered to Korean Children Completed NCT01404962 Phase 4
4 The Safety and Immunogenicity of Haemophilus Influenzae Type b Vaccine in Different Injection Site Completed NCT01761136 Phase 4
5 Assess Safety & Reactogenicity of GSK Biologicals' Hib Vaccine Co-administered With or Without Chinese DTPw Vaccine Completed NCT00158795 Phase 4
6 Study to Eliminate Hib Carriage in Rural Alaska Native Villages Completed NCT00153556 Phase 4
7 The Immediate and Longterm Immune Responses of UK Infants and Young Children to a Booster Dose of Hib Vaccine Completed NCT00197782 Phase 4
8 Study of Long-term Antibody Persistence After a Booster Dose of Menitorix Vaccine Completed NCT00454987 Phase 4
9 Hepatitis B Vaccination in Infants Completed NCT01896596 Phase 4
10 Immunogenicity of the Booster Dose of Two MenC Vaccines Completed NCT00392808 Phase 4
11 Immunogenicity and Safety of PCV13 and Fluad in Adults Aged ≥60 Years Completed NCT02215863 Phase 4
12 Trial to Evaluate Time to Symptom Relief and Elimination of Infecting Bacteria in Treating Sinusitis With Avelox Completed NCT00668304 Phase 4
13 Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora Completed NCT00312338 Phase 4
14 Phase IV Interchangeability Study of a Liquid Pentavalent Combination Vaccine Completed NCT00674908 Phase 4
15 Safety and Immunogenicity Study of a Liquid Pentavalent Combination Vaccine Completed NCT00617812 Phase 4
16 Concomitant Use of Hepatitis A Vaccine, Inactivated With Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) and Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Given to Healthy Children 15 Months of Age (V251-068) Completed NCT00289913 Phase 4
17 Assess the Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 & 18 Mths of Age, in Healthy Infants Completed NCT00325156 Phase 4
18 Assessment of the Immunogenicity and Safety of PENTAXIM™ in Philippines Completed NCT00254917 Phase 4
19 Study to Evaluate Antibody Persistence in Children Previously Vaccinated With Infanrix Hexa™ or Infanrix-IPV/Hib™ Completed NCT01358825 Phase 4
20 Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants Completed NCT00753649 Phase 4
21 Comparison of Immunogenicity and Reactogenicity of INFANRIX™ HEXA and HEXAVAC™ Vaccines as a Primary Vaccination Course Completed NCT01457547 Phase 4
22 Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age Completed NCT01659996 Phase 4
23 Retrospective Survey of Safety of Fourth Dose Pentacel® in Children Completed NCT00772369 Phase 4
24 Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand Completed NCT00255021 Phase 4
25 Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™ Completed NCT00802867 Phase 4
26 Safety of PENTAXIM® Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in China Completed NCT01491087 Phase 4
27 Study Assessing the Effect of Medications to Prevent Fever on Prevenar 13® Completed NCT01392378 Phase 4
28 Study to Assess if Quinvaxem Can be Interchanged With Other Pentavalent Vaccines During Standard Childhood Vaccination Completed NCT01357720 Phase 4
29 Efficacy and Safety of Vivaglobin® in Previously Untreated Patients With Primary Immunodeficiency Completed NCT00520494 Phase 4
30 Tripartite International Research for the Elimination of Trachoma Completed NCT01202331 Phase 4
31 Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery Recruiting NCT02422264 Phase 4
32 Vaccinating Children After Chemotherapy Recruiting NCT02447718 Phase 4
33 Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery Recruiting NCT02853929 Phase 4
34 Babies Born Early Antibody Response to Men B Vaccination: BEAR Men B Not yet recruiting NCT03125616 Phase 4
35 Study Comparing DTP-HB-Hib by Disposable-Syringe Jet Injector To Vaccination By Needle And Syringe In Infants Terminated NCT02409095 Phase 4
36 Safety and Immunogenicity of 10-valent and 13-valent Pneumococcal Conjugate Vaccines in Papua New Guinean Children Unknown status NCT01619462 Phase 3
37 Randomized Study on Efficacy of Gemifloxacin-based Regimen for Helicobacter Pylori Infection Unknown status NCT02368470 Phase 3
38 Safety and Immunogenicity of a Monovalent Conjugated Vaccine Against Haemophilus Influenzae Type b Completed NCT00808392 Phase 3
39 Study in Toddlers (12-18 Months) Comparing a Booster Dose of Vaxem Hib and Hiberix Vaccines for the Prevention of Haemophilus Influenzae Type b Infections in China Completed NCT01025544 Phase 3
40 Study in Infants (6-12 Months) Comparing Two Doses of a Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Vaccine Versus a Tetanus Toxoid-Conjugated Vaccine Available for the Prevention of Haemophilus Influenzae Type b Infections in China Completed NCT01044316 Phase 3
41 A Phase III Clinical Trial of a Haemophilus Influenzae Type b (Hib) Conjugate Vaccine Completed NCT02692859 Phase 3
42 Immunogenicity and Safety of a Booster Dose of Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Hib Vaccine in 365-569 Days Old Healthy Infants Completed NCT01226953 Phase 3
43 Persistency Study After Hib-CRM (Cross-Reacting Material)197 or Hib-TT (Tetanus Toxoid) Vaccines in Chinese Children Completed NCT02139228 Phase 3
44 Study of Modified Process Hib/Hep B Vaccine in Infants (V121-019)(COMPLETED) Completed NCT00441012 Phase 3
45 Immunogenicity and Safety of a Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Hib Vaccine in 13-59 Months Old Healthy Children Completed NCT01125527 Phase 3
46 Immunogenicity and Safety Study of LBVH0101 in Healthy Infants at Two, Four and Six Months of Age Completed NCT01019772 Phase 3
47 Study of Quinvaxem for Vaccination Against Diphtheria, Pertussis, Tetanus, Hepatitis B and Diseases Caused by Haemophilus Influenzae Type B Completed NCT01362517 Phase 3
48 Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age Completed NCT00345579 Phase 3
49 Study of an Investigational Vaccine in Healthy Infants in Taiwan (V441-001)(COMPLETED) Completed NCT00092469 Phase 3
50 Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC & to Evaluate Persistence up to 5 Years. Completed NCT00326118 Phase 3

Search NIH Clinical Center for Haemophilus Influenzae

Genetic Tests for Haemophilus Influenzae

Anatomical Context for Haemophilus Influenzae

MalaCards organs/tissues related to Haemophilus Influenzae:

39
Colon, Lung, Tonsil, Monocytes, Testes, Neutrophil, B Cells

Publications for Haemophilus Influenzae

Articles related to Haemophilus Influenzae:

(show top 50) (show all 559)
id Title Authors Year
1
Cephalosporin-3'-Diazeniumdiolate NO Donor Prodrug PYRRO-C3D Enhances Azithromycin Susceptibility of Nontypeable Haemophilus influenzae Biofilms. ( 27919896 )
2017
2
Antimicrobial activity of antisense peptide-peptide nucleic acid conjugates against non-typeable Haemophilus influenzae in planktonic and biofilm forms. ( 27986898 )
2017
3
Resistance of non-typeable Haemophilus influenzae biofilms is independent of biofilm size. ( 27956464 )
2017
4
Budget impact analysis of vaccination against Haemophilus influenzae type b as a part of a Pentavalent vaccine in the childhood immunization schedule of Iran. ( 28088246 )
2017
5
Vaccine Candidates against Nontypeable Haemophilus influenzae: a Review ( 28088130 )
2017
6
Bacteremic renal stone-associated urinary tract infection caused by nontypable Haemophilus influenzae: A rare invasive disease in an immunocompetent patient. ( 27920983 )
2017
7
Haemophilus influenzae Serotype f Epiglottitis: A Case Report and Review. ( 28028010 )
2017
8
Pneumonia prevention: Cost-effectiveness analyses of two vaccines among refugee children aged under two years, Haemophilus influenzae type b-containing and pneumococcal conjugate vaccines, during a humanitarian emergency, Yida camp, South Sudan. ( 27989625 )
2017
9
Response to Effectiveness of the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein D-Conjugated Vaccine (PHiD-CV) Against Carriage and Acute Otitis Media-A Double-Blind Randomized Clinical Trial in Finland. ( 28064237 )
2017
10
Haemophilus influenzae Type b Invasive Disease in Amish Children, Missouri, USA, 2014. ( 27983486 )
2017
11
Biochemical characterization of TyrA enzymes from Ignicoccus hospitalis and Haemophilus influenzae: A comparative study of the bifunctional and monofunctional dehydrogenase forms. ( 28025081 )
2016
12
Changes in the prevalence and biofilm formation of Haemophilus influenzae and Haemophilus parainfluenzae from the respiratory microbiota of patients with sarcoidosis. ( 27562460 )
2016
13
Defining the Binding Region in Factor H to Develop a Therapeutic Factor H-Fc Fusion Protein against Non-Typeable Haemophilus influenzae. ( 27148489 )
2016
14
Host-pathogen interactions of nontypeable Haemophilus influenzae: from commensal to pathogen. ( 27508518 )
2016
15
Density, serotype diversity, and fitness of Streptococcus pneumoniae in upper respiratory co-colonization with nontypeable Haemophilus influenzae. ( 27540112 )
2016
16
Natural development of antibodies against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis protein antigens during the first 13 years of life. ( 27581439 )
2016
17
Effects of prophylactic ibuprofen and paracetamol administration on the immunogenicity and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugated vaccine (PHiD-CV) co-administered with DTPa-combined vaccines in children: An open-label, randomized, controlled, non-inferiority trial. ( 27541270 )
2016
18
IgE anti-haemophilus influenzae type b (Hib) antibodies detected in serum of Hib vaccinated asthmatic and non-asthmatic pediatric patients. ( 27187042 )
2016
19
Phase I, randomized, observer-blind, placebo-controlled studies to evaluate the safety, reactogenicity and immunogenicity of an investigational non-typeable Haemophilus influenzae (NTHi) protein vaccine in adults. ( 27133877 )
2016
20
Bacterial Tracheitis Caused by Haemophilus influenzae after Influenza. ( 27086830 )
2016
21
Microbiological Characterization of Haemophilus influenzae Isolated from Patients with Lower Respiratory Tract Infections in a Tertiary Care Hospital, South India. ( 27437218 )
2016
22
In Vitro Activity of Delafloxacin Tested against Isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. ( 27458220 )
2016
23
Early life intranasal colonization with nontypeable Haemophilus influenzae exacerbates juvenile airways disease in mice. ( 27113355 )
2016
24
Non-typeable Haemophilus influenzae protects human airway epithelial cells from a subsequent respiratory syncytial virus challenge. ( 27573069 )
2016
25
A Novel, Molybdenum-Containing Methionine Sulfoxide Reductase Supports Survival of Haemophilus influenzae in an In vivo Model of Infection. ( 27933034 )
2016
26
A high throughput serum bactericidal assay for antibodies to Haemophilus influenzae type b. ( 27595992 )
2016
27
Antibodies from multiple sclerosis patients preferentially recognize hyperglucosylated adhesin of non-typeable Haemophilus influenzae. ( 28008952 )
2016
28
Haemophilus influenzae in COPD: Effect of fluoroquinolones and macrolides on eradication and resistance. ( 27139476 )
2016
29
Prevalence and antimicrobial susceptibility of Haemophilus influenzae and Moraxella catarrhalis isolated from patients in Bangkok, Thailand. ( 27436474 )
2016
30
An Atypical I+/I^-Hydrolase Fold Revealed in the Crystal Structure of Pimeloyl-Acyl Carrier Protein Methyl Esterase BioG from Haemophilus influenzae. ( 27933801 )
2016
31
Emergence and molecular characterization of Haemophilus influenzae harbouring mef(A). ( 27999037 )
2016
32
Immunogenicity and Safety Of 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Administered to Children with Sickle Cell Disease Between 8 Weeks and 2 Years of Age: A Phase III, Open, Controlled Study. ( 28030521 )
2016
33
Immunization with Protein D from Non-Typeable Haemophilus influenzae (NTHi) Induced Cytokine Responses and Bioactive Antibody Production. ( 27942362 )
2016
34
Interleukin-22 protects against non-typeable Haemophilus influenzae infection: alteration during chronic obstructive pulmonary disease. ( 27143304 )
2016
35
An antagonist of the platelet-activating factor receptor inhibits adherence of both nontypeable Haemophilus influenzae and Streptococcus pneumoniae to cultured human bronchial epithelial cells exposed to cigarette smoke. ( 27524890 )
2016
36
Applying Central Composite Design and Response Surface Methodology to Optimize Growth and Biomass Production of Haemophilus influenzae Type b. ( 27630761 )
2016
37
Prevalence of macrolide-non-susceptible isolates among I^-lactamase-negative ampicillin-resistant Haemophilus influenzae in a tertiary care hospital in Japan. ( 27530834 )
2016
38
Streptococcus pneumoniae and Haemophilus influenzae type b carriage in Chinese children aged 12-18 months in Shanghai, China: a cross-sectional study. ( 27080523 )
2016
39
Morphological changes in the round window membrane associated with Haemophilus influenzae-induced acute otitis media in the chinchilla. ( 27497390 )
2016
40
Antibacterial FabH Inhibitors with Mode of Action Validated in Haemophilus influenzae by in Vitro Resistance Mutation Mapping. ( 27626097 )
2016
41
Molecular characterisation of the clonal emergence of high-level ciprofloxacin-monoresistant Haemophilus influenzae in the Region of Southern Denmark. ( 27436470 )
2016
42
Non-Type b Haemophilus influenzae Invasive Infections in North Dakota and South Dakota, 2013-2015. ( 27656134 )
2016
43
Oldenlandia diffusa Extract Inhibits Biofilm Formation by Haemophilus influenzae Clinical Isolates. ( 27902758 )
2016
44
Seasonal patterns and association of meteorological factors with infection caused by Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in childhood community-acquired pneumonia in a tropical region. ( 27464260 )
2016
45
Distribution and Diversity of hmw1A Among Invasive Nontypeable Haemophilus influenzae Isolates in Iran. ( 27141269 )
2016
46
Antimicrobial resistance in cystic fibrosis isolates of Haemophilus influenzae. ( 27181174 )
2016
47
Structural basis for haem piracy from host haemopexin by Haemophilus influenzae. ( 27188378 )
2016
48
Antibody Persistence in Young Children 5 Years after Vaccination with Combined Haemophilus influenzae type b-Neisseria meningitidis Serogroup C or MenC Conjugate Vaccines Co-Administered with DTPa-Containing and Pneumococcal Conjugate Vaccines. ( 27145999 )
2016
49
Effect of epithelial cell type on in vitro invasion of non-typeable Haemophilus influenzae. ( 27473508 )
2016
50
Non-Type b Haemophilus influenzae Septic Arthritis in Children. ( 27150112 )
2016

Variations for Haemophilus Influenzae

Expression for Haemophilus Influenzae

Search GEO for disease gene expression data for Haemophilus Influenzae.

Pathways for Haemophilus Influenzae

Pathways related to Haemophilus Influenzae according to GeneCards Suite gene sharing:

(show all 15)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.61 CXCL8 CYLD TLR2 TNF
2
Show member pathways
12.06 CXCL8 TLR2 TNF
3 12.01 TLR2 TNF VTN
4
Show member pathways
11.97 CXCL8 TLR2 TNF
5 11.92 CLEC7A TLR2 TNF
6
Show member pathways
11.83 CXCL8 TLR2 TNF
7 11.79 CXCL8 TF TNF
8 11.48 CXCL8 TLR2 TNF
9 11.39 CXCL8 TLR2 TNF
10 11.26 CLEC7A TLR2 VTN
11 10.87 CXCL8 TLR2 TNF
12 10.86 CXCL8 TNF
13 10.82 CYLD TNF
14 10.65 CXCL8 TNF
15 10.49 CXCL8 TLR2 TNF

GO Terms for Haemophilus Influenzae

Cellular components related to Haemophilus Influenzae according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.02 LTF PKD1 TF TLR2 TNF

Biological processes related to Haemophilus Influenzae according to GeneCards Suite gene sharing:

(show all 12)
id Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.73 CXCL8 TLR2 TNF VTN
2 retina homeostasis GO:0001895 9.51 LTF TF
3 lipopolysaccharide-mediated signaling pathway GO:0031663 9.49 TLR2 TNF
4 regulation of tumor necrosis factor-mediated signaling pathway GO:0010803 9.48 CYLD TNF
5 positive regulation of interleukin-8 production GO:0032757 9.46 TLR2 TNF
6 positive regulation of NF-kappaB import into nucleus GO:0042346 9.4 TLR2 TNF
7 positive regulation of receptor-mediated endocytosis GO:0048260 9.37 TF VTN
8 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.33 LTF TLR2 TNF
9 embryonic digestive tract development GO:0048566 9.32 CXCL8 TNF
10 positive regulation of chemokine production GO:0032722 9.26 TLR2 TNF
11 inflammatory response GO:0006954 9.26 CLEC7A CXCL8 TLR2 TNF
12 response to molecule of bacterial origin GO:0002237 8.62 CXCL8 TLR2

Molecular functions related to Haemophilus Influenzae according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 lipopolysaccharide binding GO:0001530 8.96 LTF TLR2
2 signaling pattern recognition receptor activity GO:0008329 8.62 CLEC7A TLR2

Sources for Haemophilus Influenzae

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....